Adipose tissue in renal disease: Clinical significance and prognostic implications

Nephrology Dialysis Transplantation

Volumn 25, Issue 7, 2010, Pages 2066-2077

  Iglesias, Pedro ^a   Díez, Juan J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

adipokines; adipose; disease; kidney; obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL FAT; ABDOMINAL OBESITY; ADIPOSE TISSUE; ANTHROPOMETRIC PARAMETERS; BODY COMPOSITION; BODY HEIGHT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMODIALYSIS; HUMAN; HYDRATION; HYPERTENSION; IMPEDANCE; KIDNEY DISEASE; KIDNEY INJURY; LIPID STORAGE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUBCUTANEOUS FAT; UREMIA; WAIST HIP RATIO; COMPLICATION; KIDNEY DISEASES; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR;

ADIPOKINES; ADIPOSE TISSUE; HUMANS; KIDNEY DISEASES; OBESITY; PROGNOSIS; RISK FACTORS;

EID: 77954324300     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq246     Document Type: Review

References (165)

1. Bays HE, Gonzalez-Campoy JM, Bray GA et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6: 343-368
2. Shen W, Punyanitya M, Chen J et al. Waist circumference correlates with metabolic syndrome indicators better than percentage fat. Obesity (Silver Spring) 2006; 14: 727-736
3. Vega GL, Adams-Huet B, Peshock R et al. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endo-crinol Metab 2006; 91: 4459-4466
4. Scaglione R, Di Chiara T, Cariello T et al. Visceral obesity and metabolic syndrome: two faces of the same medal? Intern Emerg Med 2010; In press
5. Rheaume C, Arsenault BJ, Belanger S et al. Low cardiorespiratory fitness levels and elevated blood pressure: what is the contribution of visceral adiposity? Hypertension 2009; 54: 91-97
6. Fabbrini E, Magkos F, Mohammed BS et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-15435
7. Cancello R, Tordjman J, Poitou C et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-1561
8. Apovian CM, Bigornia S, Mott M et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008; 28: 1654-1659
9. Harman-Boehm I, Bluher M, Redel H et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab 2007; 92: 2240-2247
10. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738
11. Rosito GA, Massaro JM, Hoffmann U et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008; 117: 605-613
12. Adelman RD. Obesity and renal disease. Curr Opin Nephrol Hyper-tens 2002; 11: 331-335
13. Praga M. Obesity\a neglected culprit in renal disease. Nephrol Dial Transplant 2002; 17: 1157-1159
14. Abrass CK. Overview: obesity: what does it have to do with kidney disease? J Am Soc Nephrol 2004; 15: 2768-2772
15. Rutkowski P, Klassen A, Sebekova K et al. Renal disease in obesity: the need for greater attention. J Ren Nutr 2006; 16: 216-223
16. Wolf G. After all those fat years: renal consequences of obesity. Nephrol Dial Transplant 2003; 18: 2471-2474
17. Mulyadi L, Stevens C, Munro S et al. Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. Ann Nutr Metab 2001; 45: 67-71
18. Curhan GC, Willett WC, Rimm EB et al. Body size and risk of kidney stones. J Am Soc Nephrol 1998; 9: 1645-1652
19. Siener R, Glatz S, Nicolay C et al. The role of overweight and obesity in calcium oxalate stone formation. Obes Res 2004; 12: 106-113
20. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293: 455-462
21. Asplin JR. Obesity and urolithiasis. Adv Chron Kidney Dis 2009; 16: 11-20
22. Lee SC, Kim YJ, Kim TH et al. Impact of obesity in patients with urolithiasis and its prognostic usefulness in stone recurrence. J Urol 2008; 179: 570-574
23. Eisner BH, Eisenberg ML, Stoller ML. Influence of body mass index on quantitative 24-hour urine chemistry studies in children with nephrolithiasis. J Urol 2010; In press
24. Li WM, Chou YH, Li CC et al. Association of body mass index and urine pH in patients with urolithiasis. Urol Res 2009; 37: 193-196
25. Klinghoffer Z, Yang B, Kapoor A et al. Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations. Expert Rev Anticancer Ther 2009; 9: 975-987
26. Pischon T, Lahmann PH, Boeing H et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006; 118: 728-738 (Pubitemid 43076024)
27. Lowrance WT, Thompson RH, Yee DS et al. Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int 2010; 105: 16-20
28. Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol 2001; 19: 270-279
29. Gago-Dominguez M, Castelao JE. Lipid peroxidation and renal cell carcinoma: further supportive evidence and new mechanistic insights. Free Radic Biol Med 2006; 40: 721-733
30. Horiguchi A, Sumitomo M, Asakuma J et al. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol 2006; 176: 1631-1635
31. Spyridopoulos TN, Petridou ET, Dessypris N et al. Inverse association of leptin levels with renal cell carcinoma: results from a case-control study. Hormones (Athens) 2009; 8: 39-46
32. Horiguchi A, Ito K, Sumitomo M et al. Decreased serum adiponec-tin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2008; 38: 106-111
33. Hsu CY, Iribarren C, McCulloch CE et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169: 342-350
34. Foster MC, Hwang SJ, Larson MG et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52: 39-48
35. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509
36. Tran HA. Obesity-related glomerulopathy. J Clin Endocrinol Metab 2004; 89: 6358
37. Roszkowska-Blaim M. Influence of obesity in children on kidney. Przegl Lek 2006; 3: 25-28
38. Ramkumar N, Cheung AK, Pappas LM et al. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr 2004; 14: 201-207
39. Knight SF, Imig JD. Obesity, insulin resistance, and renal function. Microcirculation 2007; 14: 349-362
40. de Jong PE, Verhave JC, Pinto-Sietsma SJ et al. PREVEND Study Group. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 4: S21-S24
41. Axelsson J, Moller HJ, Witasp A et al. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis 2006; 48: 916-925
42. Elsayed EF, Sarnak MJ, Tighiouart H et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis 2008; 52: 29-38 (Pubitemid 351853273)
43. Noori N, Hosseinpanah F, Nasiri AA et al. Comparison of overall obesity and abdominal adiposity in predicting chronic kidney disease incidence among adults. J Ren Nutr 2009; 19: 228-237
44. Pinto-Sietsma SJ, Navis G, Janssen WM et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003; 41: 733-741
45. Sebekova K, Klassen A, Bahner U et al. Overweight and obesity\risk factors in the development and progression of renal disease. Vnitr Lek 2004; 50: 544-549 (Pubitemid 38902449)
46. Ejerblad E, Fored CM, Lindblad P et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-1702
47. Marchesi C, Ebrahimian T, Angulo O et al. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension 2009; 54: 1384-1392
48. Hunley TE, Ma LJ, Kon V. Scope and mechanisms of obesity-related renal disease. Curr Opin Nephrol Hypertens 2010; In press
49. Lo JC, Go AS, Chandra M et al. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis 2007; 50: 552-558
50. Lavie CJ, Milani RV. Obesity and cardiovascular disease: the Hippocrates paradox? J Am Coll Cardiol 2003; 42: 677-679
51. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-1932
52. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol 2009; 29: 3-14
53. Honda H, Qureshi AR, Axelsson J et al. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 2007; 86: 633-638
54. Kalantar-Zadeh K, Kuwae N, Wu DY et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006; 83: 202-210
55. Ishimura E, Okuno S, Kim M et al. Increasing body fat mass in the first year of hemodialysis. J Am Soc Nephrol 2001; 12: 1921-1926
56. Qureshi AR, Alvestrand A, Danielsson A et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53: 773-782
57. Axelsson J. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol Dial Transplant 2008; 23: 3041-3046
58. Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis 2003; 41: 925-932
59. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006; 151: 57-69
60. Mafra D, Guebre-Egziabher F, Fouque D. Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant 2008; 23: 2461-2466
61. Nishizawa Y, Shoji T, Ishimura E. Body composition and cardiovascular risk in hemodialysis patients. J Ren Nutr 2006; 16: 241-244 (Pubitemid 43975008)
62. Friedman AN. Adiposity in dialysis: good or bad? Semin Dial 2006; 19: 136-140
63. Chazot C, Gassia JP, Di Benedetto A et al. Is there any survival advantage of obesity in Southern European haemodialysis patients? Nephrol Dial Transplant 2009; 24: 2871-2876
64. de Mutsert R, Snijder MB, van der Sman-de Beer F et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007; 18: 967-974
65. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808 (Pubitemid 36315558)
66. Ikizler TA. Resolved: being fat is good for dialysis patients: the Godzilla effect: pro. J Am Soc Nephrol 2008; 19: 1059-1062
67. Stenvinkel P, Lindholm B. Resolved: being fat is good for dialysis patients: the Godzilla effect: con. J Am Soc Nephrol 2008; 19: 1062-1064
68. Fujino Y, Ishimura E, Okuno S et al. Annual fat mass change is a significant predictor of mortality in female hemodialysis patients. Biomed Pharmacother 2006; 60: 253-257
69. Odamaki M, Furuya R, Ohkawa S et al. Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2427-2432
70. Gotoh H, Gohda T, Tanimoto M et al. Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemo-dialysis patients. Nephrol Dial Transplant 2009; 24: 3474-3480
71. Cordeiro AC, Qureshi AR, Stenvinkel P et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2010; 25: 562-568
72. Axelsson J, Carrero JJ, Avesani CM et al. Adipokine signaling in the peritoneal dialysis patient. Contrib Nephrol 2006; 150: 166-173 (Pubitemid 44155347)
73. Fernstrom A, Hylander B, Moritz A et al. Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18: 166-171
74. Klim RA, Williamson DH. Effects of glucose-containing peritoneal-dialysis solutions on rates of lipogenesis in vivo in the liver, brown and white adipose tissue of chronic uraemic rats. Biochem J 1983; 214: 459-464
75. Grzegorzewska AE. The role of nutritional status in the outcome of peritoneal dialysis patients. Panminerva Med 2009; 51: 163-173
76. de Mutsert R, Grootendorst DC, Boeschoten EW et al. Is obesity associated with a survival advantage in patients starting peritoneal dialysis? Contrib Nephrol 2009; 163: 124-131
77. Abbott KC, Glanton CW, Trespalacios FC et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004; 65: 597-605
78. Lu Q, Cheng LT, Wang T et al. Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J Ren Nutr 2008; 18: 495-502
79. Chumlea WC. Anthropometric and body composition assessment in dialysis patients. Semin Dial 2004; 17: 466-470
80. Dwyer JT, Larive B, Leung J et al. Nutritional status affects quality of life in Hemodialysis (HEMO) Study patients at baseline. J Ren Nutr 2002; 12: 213-223
81. Locatelli F, Manzoni C, Del Vecchio L et al. Changes in the clinical condition of haemodialysis patients. J Nephrol 1999; 2: S82-S91
82. Chumlea WC, Dwyer J, Bergen C et al. Nutritional status assessed from anthropometric measures in the HEMO study. J Ren Nutr 2003; 13: 31-38
83. Davenport A, Willicombe MK. Does diabetes mellitus predispose to increased fluid overload in peritoneal dialysis patients? Nephron Clin Pract 2010; 114: c60-c66
84. Jager KJ, Merkus MP, Huisman RM et al. Nutritional status over time in hemodialysis and peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1272-1279
85. Qureshi AR, Alvestrand A, Divino-Filho JC et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemo-dialysis patients. J Am Soc Nephrol 2002; 1: S28-S36
86. Kaysen GA, Kotanko P, Zhu F et al. Estimation of adipose pools in hemodialysis patients from anthropometric measures. J Ren Nutr 2008; 18: 473-478
87. Sanches FM, Avesani CM, Kamimura MA et al. Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis 2008; 52: 66-73
88. Soto Gonzalez A, Bellido D, Buno MM et al. Predictors of the metabolic syndrome and correlation with computed axial tomography. Nutrition 2007; 23: 36-45
89. Bouza A, Bellido D, Rodríguez B et al. Estimación de la grasa abdominal visceral y subcutánea en pacientes obesos a través de ecuaciones de regresión antropométricas. Rev Esp Obesidad 2008; 6: 153-162
90. Zhou Z, Hu D, Chen J. Association between obesity indices and blood pressure or hypertension: which index is the best? Public Health Nutr 2009; 12: 1061-1071
91. Valdez R, Seidell JC, Ahn YI et al. A new index of abdominal adiposity as an indicator of risk for cardiovascular disease. A cross-population study. Int J Obes Relat Metab Disord 1993; 17: 77-82
92. DeVita MV, Stall SH. Dual-energy X-ray absorptiometry: a review. J Ren Nutr 1999; 9: 178-181
93. Barreto Silva MI, Avesani CM, Vale B et al. Agreement between anthropometry and bioelectrical impedance for measuring body fat in nonobese and obese nondialyzed chronic kidney disease patients. J Ren Nutr 2008; 18: 355-362
94. Jha V, Jairam A, Sharma MC et al. Body composition analysis with bioelectric impedance in adult Indians with ESRD: comparison with healthy population. Kidney Int 2006; 69: 1649-1653
95. Young JA, Hwang SJ, Sarnak MJ et al. Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol 2008; 3: 1786-1791
96. Kaysen GA, Kotanko P, Zhu F et al. Relationship between adiposity and cardiovascular risk factors in prevalent hemodialysis patients. J Ren Nutr 2009; 19: 357-364
97. Roubicek T, Bartlova M, Krajickova J et al. Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease. Nutrition 2009; 25: 762-768
98. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia\the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233
99. Kataoka H, Sharma K. Renal handling of adipokines. Contrib Nephrol 2006; 151: 91-105
100. Axelsson J, Heimburger O, Lindholm B et al. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 2005; 15: 131-136
101. Chudek J, Adamczak M, Nieszporek T et al. The adipose tissue as an endocrine organ\a nephrologists? perspective. Contrib Nephrol 2006; 151: 70-90
102. Zoccali C, Tripepi G, Cambareri F et al. Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. J Ren Nutr 2005; 15: 125-130
103. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141 (Pubitemid 34042020)
104. Rao M, Li L, Tighiouart H et al. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008; 23: 2619-2628
105. Diez JJ, Estrada P, Bajo MA et al. High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol 2009; 30: 244-252
106. Ntyintyane L, Panz V, Raal FJ et al. Leptin, adiponectin, and high-sensitivity C-reactive protein in relation to the metabolic syndrome in urban South African blacks with and without coronary artery disease. Metab Syndr Relat Disord 2009; 7: 243-248
107. Shoji T, Nishizawa Y, Emoto M et al. Renal function and insulin resistance as determinants of plasma leptin levels in patients with NIDDM. Diabetologia 1997; 40: 676-679
108. Parry RG, Johnson DW, Carey DG et al. Serum leptin correlates with fat mass but not dietary energy intake in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18: 569-575
109. Nishikawa M, Takagi T, Yoshikawa N et al. Measurement of serum leptin in patients with chronic renal failure on hemodialysis. Clin Nephrol 1999; 51: 296-303
110. Diez JJ, Iglesias P, Fernandez-Reyes MJ et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endo-crinol (Oxf) 2005; 62: 242-249
111. Kastarinen H, Kesaniemi YA, Ukkola O. Leptin and lipid metabolism in chronic kidney failure. Scand J Clin Lab Invest 2009; 69: 401-408
112. Heimburger O, Lonnqvist F, Danielsson A et al. Serum immunore-active leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8: 1423-1430 (Pubitemid 27491233)
113. Scholze A, Tepel M. Role of leptin in reverse epidemiology in chronic kidney disease. Semin Dial 2007; 20: 534-538
114. Wolf G, Chen S, Han DC et al. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1-11
115. Karsenty G Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 2006; 4: 341-348
116. Shinoda Y, Yamaguchi M, Ogata N et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006; 99: 196-208
117. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469
118. Mikhail AA, Beck EX, Shafer A et al. Leptin stimulates fetal and adult erythroid and myeloid development. Blood 1997; 89: 1507-1512
119. Axelsson J, Qureshi AR, Heimburger O et al. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis 2005; 46: 628-634
120. Schiller PC, D'Ippolito G, Brambilla R et al. Inhibition of gap-junctional communication induces the trans-differentiation of osteo-blasts to an adipocytic phenotype in vitro. J Biol Chem 2001; 276: 14133-14138
121. Heimburger O, Stenvinkel P. Adipokines in chronic kidney disease\fat tissue gives nephrologists a message. Perit Dial Int 2005; 25: 340-342
122. Nordfors L, Lonnqvist F, Heimburger O et al. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54: 1267-1275
123. Mallamaci F, Tripepi G, Zoccali C. Leptin in end stage renal disease (ESRD): a link between fat mass, bone and the cardiovascular system. J Nephrol 2005; 18: 464-468
124. Stenvinkel P, Heimburger O, Lonnqvist F. Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Nephrol Dial Transplant 1997; 12: 1321-1325 (Pubitemid 27353018)
125. Scholze A, Rattensperger D, Zidek W et al. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) 2007; 15: 1617-1622
126. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300
127. Sowers JR. Endocrine functions of adipose tissue: focus on adipo-nectin. Clin Cornerstone 2008; 9: 32-40
128. Zoccali C, Mallamaci F, Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int Suppl 2003; 84: S65-S68
129. Lee CT, Lee CH, Su Y et al. The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs 2004; 27: 835-841
130. Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004; 65: 274-281
131. Mitsnefes M, Kartal J, Khoury P et al. Adiponectin in children with chronic kidney disease: role of adiposity and kidney dysfunction. Clin J Am Soc Nephrol 2007; 2: 46-50
132. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009; 24: 1876-1883
133. Gordeladze JO, Drevon CA, Syversen U et al. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 2002; 85: 825-836
134. Zhang H, Xie H, Zhao Q et al. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in postmenopausal Chinese women. J Endocrinol Invest 2010; In press
135. Yu ZZ, Ni ZH, Gu LY et al. Adiponectin is related to carotid artery plaque and a predictor of cardiovascular outcome in a cohort of non-diabetic peritoneal dialysis patients. Blood Purif 2008; 26: 386-393
136. Drechsler C, Krane V, Winkler K et al. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009; 76: 567-575
137. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430 (Pubitemid 40139988)
138. Samal B, Sun Y, Stearns G et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-1437
139. Fukuhara A, Matsuda M, Nishizawa M et al. Retraction. Science 2007; 318: 565
140. Rongvaux A, Shea RJ, Mulks M Hetal. Pre-B-cellcolony-enhancing factor, who seexpressionisup-regulated inactivated lymphocytes, is a nicotinamide phosphoribosyl transferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 3225-3234
141. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758
142. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244
143. Carrero JJ, Witasp A, Stenvinkel P et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 2010; 25: 901-906
144. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
145. Jellema A, Plat J, Mensink RP. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest 2004; 34: 766-773
146. Arner E, Ryden M, Arner P. Tumor necrosis factor alpha and regulation of adipose tissue. N Engl J Med 2010; 362: 1151-1153
147. Macdonald C, Rush DN, Bernstein KN et al. Production of tumor necrosis factor alpha and hemodialysis. Nephron 1993; 65: 273-277
148. Pereira BJ, Shapiro L, King AJ et al. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896
149. Guarnieri G, Antonione R, Biolo G. Mechanisms of malnutrition in uremia. J Ren Nutr 2003; 13: 153-157
150. Cohen SD, Phillips TM, Khetpal Pet al. Cytokine patterns and survival in haemodialysis patients. Nephrol Dial Transplant 2010; In press
151. Aguilera A, Codoceo R, Selgas R et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 1998; 13: 1476-1483
152. Kern PA, Ranganathan S, Li C et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751
153. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850
154. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-1603
155. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005; 2: S114-S124
156. Stenvinkel P, Barany P, Heimburger O et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002; 80: 103-108
157. Pachaly MA, do Nascimento MM, Suliman ME et al. Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. Blood Purif 2008; 26: 204-210
158. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 2006; 17: S169-S173
159. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 1: S83-S88
160. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148
161. Hasuike Y, Nonoguchi H, Ito K et al. Interleukin-6 is a predictor of mortality in stable hemodialysis patients. Am J Nephrol 2009; 30: 389-398
162. Barreto DV, Barreto FC, Liabeuf S et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and predialysis patients with chronic kidney disease. Kidney Int 2010; 77: 550-556
163. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
164. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255: 439-447
165. Kielstein JT, Becker B, Graf S et al. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42: 62-66